Suppr超能文献

角膜缘上皮细胞治疗:过去、现在与未来。

Limbal epithelial cell therapy: past, present, and future.

作者信息

Utheim Tor Paaske

机构信息

Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.

出版信息

Methods Mol Biol. 2013;1014:3-43. doi: 10.1007/978-1-62703-432-6_1.

Abstract

The cornea, the clear window at the front of the eye, transmits light to the retina to enable vision. The corneal surface is renewed by stem cells located at the peripheral limbal region. These cells can be destroyed by a number of factors, including chemical burns, infections, and autoimmune diseases, which result in limbal stem cell deficiency (LSCD), a condition that can lead to blindness. Established therapy for LSCD based on ex vivo expanded limbal epithelial cells is currently at a stage of refinement. Therapy for LSCD is also rapidly evolving to include alternative cell types and clinical approaches as treatment modalities. In the present perspectives chapter, strategies to treat LSCD are discussed and advances in this important field of regenerative medicine are highlighted.

摘要

角膜是眼睛前部的透明窗口,它将光线传输至视网膜以实现视觉功能。角膜表面由位于周边角膜缘区域的干细胞进行更新。这些细胞可能会因多种因素而遭到破坏,包括化学灼伤、感染和自身免疫性疾病,这些因素会导致角膜缘干细胞缺乏症(LSCD),这种病症可能会导致失明。目前,基于体外扩增角膜缘上皮细胞的LSCD既定疗法正处于完善阶段。LSCD的治疗方法也在迅速发展,纳入了替代细胞类型和临床方法作为治疗方式。在本章的观点阐述中,我们将讨论治疗LSCD的策略,并突出这一再生医学重要领域的进展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验